Navigation Links
Questcor Reports First Quarter Financial Results
Date:4/30/2013

s on track to recover from first quarter softness, and rheumatology may well be up sharply from the first quarter."

To allow comparable analysis, the company has defined new paid prescriptions in the above paragraphs to include prescriptions covered by commercial carriers, Medicare, Medicaid and Tricare in all periods regardless of the rebate percentage applicable in those periods. The numbers do not include prescriptions filled through the Acthar free drug program.

Research and Development ProgramsQuestcor's continued strong financial performance has enabled the Company to increase investment in research programs to further clarify the potential immune-modulating properties of Acthar and identify Acthar mechanisms of action applicable to other inflammatory and auto-immune diseases with high unmet medical need. The Company is also in the process of identifying new patient populations in which to evaluate Acthar through clinical studies.  Additionally, Questcor has funded or has approved funding for approximately 70 other research projects, including company-sponsored clinical and pre-clinical studies and independent physician sponsored studies.

Label Enhancement Strategy:

  • Amyotrophic Lateral Sclerosis (ALS): Questcor has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Phase 2 clinical trial of Acthar for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The Company expects to initiate the Phase 2 study in the second quarter of 2013 and has submitted a request for Orphan Designation to FDA.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 IND trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United St
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Questcor to Report First Quarter Results on April 30, 2013
    2. Questcor Reports Fourth Quarter and Full Year 2012 Results
    3. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    4. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    5. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    6. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    8. Questcor Comments on Insurance Policy Bulletin
    9. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    10. Questcor Pharmaceuticals to Present at Investor Conferences in September
    11. Questcor Reports Second Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
    (Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
    (Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
    Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
    ... China , May 11 /PRNewswire-Asia/ -- WuXi PharmaTech ... development outsourcing company serving the,pharmaceutical, biotechnology, and medical device industries, ... , today announced its financial results for,first-quarter 2010. , ... Highlights, -- First-Quarter 2010 Net Revenues ...
    ... CITY , May 11 Dynatronics Corporation (Nasdaq: DYNT ) plans ... the morning of Monday, May 17, 2010 .   , ... Dynatronics has scheduled a conference call for investors later that day at ... in participating should call 800-861-4084 and use passcode: 9921511. , ...
    Cached Medicine Technology:WuXi PharmaTech Announces First-Quarter 2010 Results 2WuXi PharmaTech Announces First-Quarter 2010 Results 3WuXi PharmaTech Announces First-Quarter 2010 Results 4WuXi PharmaTech Announces First-Quarter 2010 Results 5WuXi PharmaTech Announces First-Quarter 2010 Results 6WuXi PharmaTech Announces First-Quarter 2010 Results 7WuXi PharmaTech Announces First-Quarter 2010 Results 8WuXi PharmaTech Announces First-Quarter 2010 Results 9WuXi PharmaTech Announces First-Quarter 2010 Results 10WuXi PharmaTech Announces First-Quarter 2010 Results 11WuXi PharmaTech Announces First-Quarter 2010 Results 12WuXi PharmaTech Announces First-Quarter 2010 Results 13WuXi PharmaTech Announces First-Quarter 2010 Results 14WuXi PharmaTech Announces First-Quarter 2010 Results 15WuXi PharmaTech Announces First-Quarter 2010 Results 16
    (Date:7/13/2014)... Recently, MyDressCity.com, one of the most ... outfits, has released its new range of elegant ... are available at discounted prices. Worldwide clients can enjoy ... In the company’s online shop, there are plenty of ... made with great materials. MyDressCity.com’s hot items are prom ...
    (Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed incident ... incident cases in 2013 to 11,568 diagnosed incident cases ... 4.35%, during the forecast period. In 2023, the US ... of aGVHD in the 6MM, with 4,989 diagnosed incident ... diagnosed incident cases of aGVHD, with 704 diagnosed incident ...
    (Date:7/13/2014)... A decreased ability to identify odors might indicate ... while examinations of the eye could indicate the ... in the brain, according to the results of ... Association International Conference 2014 (AAIC 2014) in Copenhagen. ... ability to identify odors was significantly associated with ...
    (Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... Lipitor bellwether trial has been scheduled in July of ... The Lipitor lawsuits are in the discovery process ... Judge Richard M. Gergel is presiding over the multidistrict ... were filed on behalf of individuals who allege that ...
    (Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
    Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
    ... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at ... for her seven children,all of whom live with asthma. ... new television show revealing Nytera,s story and others,behind the ... "Union Time" and it,s the only national labor-produced TV ...
    ... Mass., USA (February 7, 2008) After just seven months ... been named the 2007 Best New Journal - Science, Technology ... of the Association of American Publishers (AAP). , This honor, ... for Excellence, comes less than a year after Cell Stem ...
    ... Transcept Pharmaceuticals,Inc. today announced that Glenn A. ... the 10th Annual BIO CEO & Investor Conference ... Tuesday, February 12, 2008 at,10:15 AM Eastern Time., ... is a specialty pharmaceutical company,deriving significant new patient ...
    ... March Meeting of American Physical Society will take place March ... scientists are expected to be on hand. The principal ... materials, chemical and biological physics, fluids, polymers, and computation. , ... is both a great showcase for fundamental physics research and ...
    ... Owners and employees agree that the rising ... WASHINGTON, Feb. 7 Post-primary polling,shows small-business ... voting,segment equal to, and larger than, well-established ... The National Federation of Independent Business (NFIB), ...
    ... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
    Cached Medicine News:Health News:Cell Stem Cell named 'Best New Journal' of 2007 2Health News:Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Health News:Physics breakthroughs on tap at New Orleans conference 2Health News:Small Business Turns Out on Super Tuesday 2Health News:Small Business Turns Out on Super Tuesday 3Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3
    Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
    Gently curved shafts with pierse tips. Round, knurled handle for finger tip rotation. Excellent for atramatic grasp of corneal flap. Made in titanium....
    Narrow 12 mm jaws with fine teeth. Serrated handle with polished finish....
    Straight shafts with curved 1 x 2 teeth. Serrated handle with polished finish....
    Medicine Products: